Back

Latest Forum Topics / IX Biopharma    Last:0.02    +0.002

Post Reply

iX Biopharma Post Reply Rate topic
eric998 Supreme	10-Jul-2024 10:51        eric998 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Boring market, may go lower if contras cut loss ahberngh      ( Date: 10-Jul-2024 10:37) Posted: Pushed up tp 3.8c, now down to 3.2/3.3. Our junk market, I won' t be surprised if back to 2.8/2.9c soon. Those who rushed in kena eaten by bbs/shortists again. Vested.
Useful To Me  Not Useful To Me
ahberngh Master	10-Jul-2024 10:37        ahberngh About Contact  Quote this Post!
x 0   x 0  Alert Admin	Pushed up tp 3.8c, now down to 3.2/3.3. Our junk market, I won' t be surprised if back to 2.8/2.9c soon. Those who rushed in kena eaten by bbs/shortists again. Vested.
Useful To Me  Not Useful To Me
Luckygal Member	09-Jul-2024 22:01        Luckygal About Contact  Quote this Post!
x 0   x 0  Alert Admin	Hope this can bring the company back to profitability. SmallSmall      ( Date: 09-Jul-2024 19:28) Posted: NEWS RELEASE Breakthrough Sublingual Wafers Raise NAD+ Levels by 76% and Enhance Well-Being in Human Trial  SL-NAD+ wafers demonstrated in human trial to:  significantly increase blood NAD+ levels by 59% over two weeks and 76% over six weeks compared to baseline  improve energy levels, mood, sleep quality, mental clarity, and physical strength  be safe and well tolerated Singapore, 9 July 2024 &mdash iX Biopharma Ltd (the &ldquo Company&rdquo ), a specialty pharmaceutical company specializing in drug delivery systems and a leader in innovative healthspan nutraceuticals, announced today the top-line results from an open-label, pilot study conducted in London, United Kingdom by NAD Laboratory Ltd, evaluating the effects of its novel sublingual NAD+ (nicotinamide adenine dinucleotide) wafer (SL-NAD+) on NAD+ levels in nine healthy individuals. The study showed a significant increase in blood NAD+ levels, with an average rise of 59% at two weeks and 76% at six weeks compared to baseline. In addition to boosting NAD+ levels, the study showed that SL-NAD+ wafers also improved various aspects of health and wellness in the participants. According to a self-reported questionnaire, participants reported enhancements in energy levels, mood, sleep quality, mental clarity, and/or physical strength, which were sustained throughout the six-week study period. Moreover, SL-NAD+ wafers were safe and well tolerated. These results add to a growing body of evidence that the supplementation of NAD is a good way to improve the quality of life as one ages. However, SL-NAD+ is the only scientifically proven consumer product that delivers pure NAD+ via the oral mucosa to effectively increase NAD+ levels, making it the most direct and efficient way to boost NAD+ levels and enjoy its benefits. Its advantages include:  effective sublingual delivery for better bioavailability and quicker uptake  consistent dosing with no need for conversion to NAD+ compared to NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) precursor supplements and  in comparison to NAD+ IV drips, it is more practical, convenient, affordable, and readily available, providing a way for continuous supplementation to maintain constant, optimal NAD+ levels. " We are very pleased with the outcome of this study, which now confirms that SL-NAD+ wafers can significantly raise NAD+ levels when measured in plasma and within red blood cells,&rdquo said Dr Janakan Krishnarajah, Chief Operating Officer and Chief Medical Officer of the Company. &ldquo This achievement is made possible by the Company&rsquo s proprietary freeze-drying process, which stabilises NAD+, and our patented wafer formulation, ensuring rapid disintegration, release, and increased absorption, unlocking the full benefits of this critical molecule. This is a breakthrough for the field of longevity science and for millions of people who want to optimise their cellular health."
Useful To Me  Not Useful To Me
SmallSmall Supreme	09-Jul-2024 19:28        SmallSmall About Contact  Quote this Post!
x 0   x 0  Alert Admin	NEWS RELEASE Breakthrough Sublingual Wafers Raise NAD+ Levels by 76% and Enhance Well-Being in Human Trial  SL-NAD+ wafers demonstrated in human trial to:  significantly increase blood NAD+ levels by 59% over two weeks and 76% over six weeks compared to baseline  improve energy levels, mood, sleep quality, mental clarity, and physical strength  be safe and well tolerated Singapore, 9 July 2024 &mdash iX Biopharma Ltd (the &ldquo Company&rdquo ), a specialty pharmaceutical company specializing in drug delivery systems and a leader in innovative healthspan nutraceuticals, announced today the top-line results from an open-label, pilot study conducted in London, United Kingdom by NAD Laboratory Ltd, evaluating the effects of its novel sublingual NAD+ (nicotinamide adenine dinucleotide) wafer (SL-NAD+) on NAD+ levels in nine healthy individuals. The study showed a significant increase in blood NAD+ levels, with an average rise of 59% at two weeks and 76% at six weeks compared to baseline. In addition to boosting NAD+ levels, the study showed that SL-NAD+ wafers also improved various aspects of health and wellness in the participants. According to a self-reported questionnaire, participants reported enhancements in energy levels, mood, sleep quality, mental clarity, and/or physical strength, which were sustained throughout the six-week study period. Moreover, SL-NAD+ wafers were safe and well tolerated. These results add to a growing body of evidence that the supplementation of NAD is a good way to improve the quality of life as one ages. However, SL-NAD+ is the only scientifically proven consumer product that delivers pure NAD+ via the oral mucosa to effectively increase NAD+ levels, making it the most direct and efficient way to boost NAD+ levels and enjoy its benefits. Its advantages include:  effective sublingual delivery for better bioavailability and quicker uptake  consistent dosing with no need for conversion to NAD+ compared to NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) precursor supplements and  in comparison to NAD+ IV drips, it is more practical, convenient, affordable, and readily available, providing a way for continuous supplementation to maintain constant, optimal NAD+ levels. " We are very pleased with the outcome of this study, which now confirms that SL-NAD+ wafers can significantly raise NAD+ levels when measured in plasma and within red blood cells,&rdquo said Dr Janakan Krishnarajah, Chief Operating Officer and Chief Medical Officer of the Company. &ldquo This achievement is made possible by the Company&rsquo s proprietary freeze-drying process, which stabilises NAD+, and our patented wafer formulation, ensuring rapid disintegration, release, and increased absorption, unlocking the full benefits of this critical molecule. This is a breakthrough for the field of longevity science and for millions of people who want to optimise their cellular health."
Useful To Me  Not Useful To Me
7ocean Veteran	09-Jul-2024 15:50        7ocean About Contact  Quote this Post!
x 0   x 0  Alert Admin	I Invested this counter for a Long time, since IPO ...but the price always down and not even  1 time pay out single cents of dividend
Useful To Me  Not Useful To Me
SmallSmall Supreme	09-Jul-2024 14:14        SmallSmall About Contact  Quote this Post!
x 0   x 0  Alert Admin	This one I like. Major shareholders coming out money to subscribe for their entitlements.  Very limted downside. Right issue at $0.03 and comes with some free warrants.  Now trading @ $0.029 below rights issue price.  Those who apply for excess likely to get it. Already trading at historical low. Just buy and hold and wait for the upswing. Be patient One thing good is company will once in a while annouced tie-ups with other medical entities. Their Sublingual Wafer may surprise one day. Dated 11 MArch 2024 . NEWS RELEASE iX Biopharma Announces Development of Semaglutide Sublingual Wafer, iXB 401, Targeting Diabetes and Obesity Markets ✓ The pharmaceutical industry is responding swiftly to the soaring demand for GLP-1 drugs globally, projected to reach US$100 billion by 2030 ✓ iX Biopharma is leveraging its WaferlogiX drug delivery technology to develop iXB 401, a novel sublingual semaglutide GLP-1 receptor agonist wafer with potential advantages over other oral semaglutide drugs including enhanced absorption, improved efficacy and better side effect profile ✓ iX Biopharma intends to out-license iXB 401 and target registration and commercialization in China
Useful To Me  Not Useful To Me
GGTTAANN Senior	04-Jul-2024 11:33        GGTTAANN About Contact  Quote this Post!
x 0   x 0  Alert Admin	The pricing of R Share seems very off. What is the Mgmt doing and the F adviser? 0.03+0.06=0.09 > .031 current share price ? Decimal point error ?
Useful To Me  Not Useful To Me
Luckygal Member	12-Jun-2024 17:57        Luckygal About Contact  Quote this Post!
x 0   x 0  Alert Admin	New rights issue? Kilatkilat      ( Date: 12-Jun-2024 14:22) Posted: Anyone apply for rights shares?
Useful To Me  Not Useful To Me
Kilatkilat Senior	12-Jun-2024 14:22        Kilatkilat About Contact  Quote this Post!
x 0   x 0  Alert Admin	Anyone apply for rights shares?
Useful To Me  Not Useful To Me
GGTTAANN Senior	12-Mar-2024 06:31        GGTTAANN About Contact  Quote this Post!
x 0   x 0  Alert Admin	Let' s hope market will response to the good news ! Cheer n PDYODD Wind888      ( Date: 11-Mar-2024 20:47) Posted: iX Biopharma Announces Development of Semaglutide Sublingual Wafer, iXB 401, Targeting Diabetes and Obesity Markets
Useful To Me  Not Useful To Me
Wind888 Senior	11-Mar-2024 20:47        Wind888 About Contact  Quote this Post!
x 0   x 0  Alert Admin	iX Biopharma Announces Development of Semaglutide Sublingual Wafer, iXB 401, Targeting Diabetes and Obesity Markets
Useful To Me  Not Useful To Me
GGTTAANN Senior	16-Aug-2023 13:28        GGTTAANN About Contact  Quote this Post!
x 0   x 0  Alert Admin	The global interferon market has expanded following the COVID-19 pandemic to an estimated $7.5 billion in 2020 due to an increasing demand for the use of interferons along with antiretrovirals and antimalarial drugs in the treatment of COVID-19 patients1. Influenza and SARS-CoV2 viruses are still prevalent and cause significant morbidity and mortality despite widely available vaccination. Adjunctive strategies are required to minimize disease burden. Low dose interferon wafers could disrupt the market as a safe, effective and easy to use antiviral to prevent and treat viral illnesses like influenza, COVID-19 and RSV in both vaccinated and unvaccinated individuals. The Company will be engaging with the US FDA on designing the clinical development program required to obtain pharmaceutical registration. Once US FDA  gave the approval, the share price will be 2X 3X 5X ? Pls DYODD
Useful To Me  Not Useful To Me
newbie1118 Veteran	16-Aug-2023 13:21        newbie1118 About Contact  Quote this Post!
x 0   x 0  Alert Admin	This shares is illiquid. The buy volume can disappear overnight. U must be prepared to hold for a long time.
Useful To Me  Not Useful To Me
ahberngh Master	16-Aug-2023 12:53        ahberngh About Contact  Quote this Post!
x 0   x 0  Alert Admin	Their WaferIX drug delivery platform and ongoing enhancements to it is their most valuable asset, I think. There is an outside chance that they could be a target for big pharma in future. Just my opinion, please dyodd.
Useful To Me  Not Useful To Me
SmallSmall Supreme	16-Aug-2023 11:49        SmallSmall About Contact  Quote this Post!
x 0   x 0  Alert Admin	Not much resistance to $0.07-$0.08 where it dropped from in July 2013. Only news was athe issuance of a $2 mil CB in July but the shares are only convertible at $0.13.   SmallSmall      ( Date: 16-Aug-2023 11:20) Posted: Up 36%. Can go to 50%? Illquid stock that crashed from $0.20 plus cts GGTTAANN      ( Date: 16-Aug-2023 09:29) Posted: IX BIOPHARMA UNVEILS DEVELOPMENT OF INTERFERON WAFER TO COMBAT RESPIRATORY VIRAL DISEASES
Useful To Me  Not Useful To Me
GGTTAANN Senior	16-Aug-2023 11:42        GGTTAANN About Contact  Quote this Post!
x 0   x 0  Alert Admin	https://investors.sgx.com/company-disclosures/company-announcements?securityCode=42C Read yourself
Useful To Me  Not Useful To Me
SmallSmall Supreme	16-Aug-2023 11:20        SmallSmall About Contact  Quote this Post!
x 0   x 0  Alert Admin	Up 36%. Can go to 50%? Illquid stock that crashed from $0.20 plus cts GGTTAANN      ( Date: 16-Aug-2023 09:29) Posted: IX BIOPHARMA UNVEILS DEVELOPMENT OF INTERFERON WAFER TO COMBAT RESPIRATORY VIRAL DISEASES
Useful To Me  Not Useful To Me
ahberngh Master	16-Aug-2023 11:20        ahberngh About Contact  Quote this Post!
x 0   x 0  Alert Admin	Could be why up today! These two days drop to as low as 3.8c. Hope it is not just a dead cat bounce. This company have many promising products but getting approval and marketing very slow. Only for long term investors, contras and short term players should stay away.   GGTTAANN      ( Date: 16-Aug-2023 09:29) Posted: IX BIOPHARMA UNVEILS DEVELOPMENT OF INTERFERON WAFER TO COMBAT RESPIRATORY VIRAL DISEASES
Useful To Me  Not Useful To Me
GGTTAANN Senior	16-Aug-2023 09:29        GGTTAANN About Contact  Quote this Post!
x 0   x 0  Alert Admin	IX BIOPHARMA UNVEILS DEVELOPMENT OF INTERFERON WAFER TO COMBAT RESPIRATORY VIRAL DISEASES
Useful To Me  Not Useful To Me
cherintc Senior	04-Aug-2023 21:36        cherintc About Contact  Quote this Post!
x 0   x 0  Alert Admin	IX Biopharma Issues SG$2 Million Worth of Convertible Bonds to Private Investor. This is the death roll. The lower the share price, the bigger the dilution which in turn cause the share price to drop further.
Useful To Me  Not Useful To Me

                                                         First   < Newer   21-40 of 3400   Older>   Last